PharmacoBx
Présentation
Equipes
Enseignements
Projets
Publications
Contact
PharmacoBx
Publications
Publications scientifiques
Depuis le 27/02/2023
Dernières publications (20)
Par année
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice.
de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; Pharmacoepidemiological group of the French Society of Pharmacology and Therapeutics (SFPT).
Therapie.
2023
[Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice]
de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; au nom du groupe de pharmaco-épidémiologie de la Société Française de Pharmacologie et de Thérapeutique (SFPT).
Therapie.
2023
Drugs and the elderly: A complex interaction.
Bégaud B, de Germay S, Noize P.
Therapie.
2023
[Analyze and use the results of clinical studies in the perspective of good use. Critical analysis, clinical research and levels of evidence]
Pariente A, de Germay S.
Rev Prat.
2023
Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
Hyeraci G, Gini R, Bezin J, Iannone LF, Benemei S, Lupi C, De Cesaris F, Geppetti P, Roberto G.
Headache.
2023
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G.
J Antimicrob Chemother.
2023
Trends in use of benzodiazepines and Z-drugs in France from 2012 to 2020.
Bénard-Laribière A, Pambrun E, Diop PY, Pariente A.
Therapie.
2022
Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F.
Therapie.
2022
What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F.
Therapie.
2022
Systematic review on sex differences for drug use after stroke.
Perrier J, Renard M, Pariente A, Bezin J.
Therapie.
2022
Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F.
Psychopharmacology (Berl).
2022
Bidisciplinary dermatology-pharmacovigilance consultations: Results of a two-year study.
Sanchez-Pena P, Milpied B, Darrigade AS, Miremont-Salamé G, Pariente A, Beylot Barry M.
Ann Dermatol Venereol.
2022
Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis.
Spini A, Ciccone V, Rosellini P, Ziche M, Lucenteforte E, Salvo F, Donnini S.
Cancers (Basel).
2022
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL.
Diabetes Care.
2022
Transparency and robustness of safety signals.
Khouri C, Fusaroli M, Salvo F, Raschi E.
BMJ.
2022
Incidence of Heart Failure following Exposure to a Protein Kinase Inhibitor (PKI), a French Population-based Study.
Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, Lapeyre-Mestre M, Despas F.
Br J Clin Pharmacol.
2022
JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
Gouverneur A, Avouac J, Prati C, Cracowski JL, Schaeverbeke T, Pariente A, Truchetet ME.
Eur J Clin Pharmacol.
2022
Second-degree burn induced by high-concentration topical capsaicin with mobility sequelae: a case report.
Trin K, Perino J, Allouchery M, Géniaux H, Miremont G, Salvo F.
Pain Pract.
2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC).
Br J Haematol.
2022
Adverse drug reaction related to drug shortage: A retrospective study on the French National Pharmacovigilance Database.
Bourneau-Martin D, Babin M, Grandvuillemin A, Mullet C, Salvo F, Singier A, Cellier M, Fresse A, de Canecaude C, Pietri T, Drablier G, Geniaux H, Lagarce L, Laroche ML, Briet M; French Network of Regional Pharmacovigilance Centres.
Br J Clin Pharmacol.
2023